90825-43-7
90825-43-7 structure
- Name: Mifamurtide sodium
- Chemical Name: 21G81IKJ8L
- CAS Number: 90825-43-7
- Molecular Formula: C59H108N6NaO19P
- Molecular Weight: 1259.481
- Catalog: Research Areas Cancer
- Create Date: 2018-06-06 10:29:36
- Modify Date: 2024-01-09 21:01:37
-
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide sodium has the potential for osteosarcoma research[1][2][3].
| Name | 21G81IKJ8L |
|---|---|
| Synonyms |
D-Glucose, 2-(acetylamino)-3-O-[(1R)-2-[[(1S)-2-[[(1R)-1-(aminocarbonyl)-4-[[(1S)-2-[[2-[[[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]hydroxyphosphinyl]oxy]ethyl]amino]-1-methyl-2-oxoethyl]amino]-4-oxobutyl]amino]-1-methyl-2-oxoethyl]amino]-1-methyl-2-oxoethyl]-2-deoxy-, sodium salt (1:1)
Sodium (2R)-2,3-bis(palmitoyloxy)propyl (4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-[(1R,2R)-1,2,3-trihydroxypropyl]-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl phosphate 21G81IKJ8L |
| Description | Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide sodium has the potential for osteosarcoma research[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Mifamurtide sodium (MTP-PE sodium; 100 µM) induces a reduction of MG63 cells number when co-cultured with macrophages[3]. Mifamurtide sodium (100 µM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide sodium increases the iron transporter DMT1 protein[3]. L-mifamurtide sodium (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo[1]. Mifamurtide sodium acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2[3]. |
| In Vivo | Mifamurtide sodium (MTP-PE sodium; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination[1]. Mifamurtide sodium (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide sodium (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass[2]. Animal Model: C57BL/6, BALB/c mice with KHOS osteosarcoma cells[1] Dosage: 1 mg/kg Administration: IV; twice per week for 4 weeks Result: Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models. |
| References |
| Molecular Formula | C59H108N6NaO19P |
|---|---|
| Molecular Weight | 1259.481 |
| Exact Mass | 1258.730469 |